Zai Lab Ltd — Director's Dealing 2021

Sep 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Zai Lab Ltd (ZLAB)
CIK: 0001704292
Period of Report: 2021-09-07

Reporting Person: Reinhart Harald (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-07	Ordinary Shares	M	10000	$3.00	Acquired	10000	Direct
2021-09-07	Ordinary Shares	S	100	$143.00	Disposed	9900	Direct
2021-09-07	Ordinary Shares	S	200	$146.98	Disposed	9700	Direct
2021-09-07	Ordinary Shares	S	300	$148.69	Disposed	9400	Direct
2021-09-07	Ordinary Shares	S	2000	$150.41	Disposed	7400	Direct
2021-09-07	Ordinary Shares	S	6600	$151.28	Disposed	800	Direct
2021-09-07	Ordinary Shares	S	800	$152.11	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-07	Stock Options (Right to Buy)	$3.00	M	10000	Disposed	2027-05-12	Ordinary Shares (10000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2: Reflects a weighted average sale price of $146.98 per share, at prices ranging from $146.66 to $147.30 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F3: Reflects a weighted average sale price of $148.69 per share, at prices ranging from $148.23 to $148.92 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F4: Reflects a weighted average sale price of $150.41 per share, at prices ranging from $149.80 to $150.78 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F5: Reflects a weighted average sale price of $151.28 per share, at prices ranging from $150.84 to $151.82 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F6: Reflects a weighted average sale price of $152.11 per share, at prices ranging from $151.85 to $152.50 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F7: The options vest in equal annual installments over four years beginning on 5/12/2018, the first anniversary of the date of grant.